Lab Reference Library / Urinary PGD2 Metabolite
Inflammation and Immune
Urinary PGD2 Metabolite
11-beta-PGF2α · Prostaglandin D2 Metabolite · 2,3-dinor-11-beta-PGF2αReference range, clinical significance, and why urinary prostaglandin D2 metabolite is the most mast cell-specific mediator marker available. Unlike histamine (produced by mast cells, basophils, and gut bacteria) and tryptase (which may be normal in many MCAS patients), PGD2 is produced almost exclusively by mast cells, making its metabolite the most specific indicator of mast cell activation.
Mast Cell SpecificMCAS Evaluation
ReferenceLab-specific
ElevatedAbove ULN
CollectionSpot or 24-hr urine
Keep RefrigeratedYes
← Back to Lab Reference Library
Category: Inflammation and Immune | Also known as: 11-beta-PGF2α, Prostaglandin D2 Metabolite, 2,3-dinor-11-beta-PGF2α | Sample: Spot urine (creatinine-corrected) or 24-hour urine; refrigerated
1. What This Test Measures
Urinary prostaglandin D2 metabolite measures the stable downstream products of prostaglandin D2 (PGD2) excreted in urine. PGD2 is a lipid mediator synthesized from arachidonic acid through the cyclooxygenase (COX) pathway, specifically by the enzyme hematopoietic prostaglandin D synthase (H-PGDS). PGD2 itself is unstable in biological fluids and is rapidly metabolized to 11-beta-prostaglandin F2-alpha (11-beta-PGF2alpha) and then to 2,3-dinor-11-beta-PGF2alpha, both of which are stable and measurable in urine.
The defining clinical characteristic of PGD2 is its cellular source: it is produced almost exclusively by mast cells. While histamine is released by mast cells, basophils, gastric enterochromaffin-like cells, and histamine-producing gut bacteria, PGD2 production is overwhelmingly mast cell-specific. This makes urinary PGD2 metabolite the most specific indicator available for confirming that mast cells are the source of mediator excess. When tryptase is normal (reflecting normal mast cell number) and urinary N-methylhistamine could be elevated from non-mast-cell sources, an elevated PGD2 metabolite definitively points to mast cell activation.
PGD2 mediates several of the clinical effects of mast cell activation through its downstream metabolites. PGD2 itself causes bronchoconstriction, vasodilation, and flushing through DP1 and DP2 (CRTH2) receptors. Its metabolite 9-alpha,11-beta-PGF2 causes airway constriction. Another metabolite, 15-deoxy-delta-12,14-PGJ2, has anti-inflammatory effects through PPAR-gamma activation, creating a paradoxical situation where mast cell PGD2 has both pro-inflammatory and anti-inflammatory downstream effects depending on which metabolic pathway predominates.
2. Why This Test Matters
- Most mast cell-specific mediator: PGD2 is produced almost exclusively by mast cells. Elevated urinary PGD2 metabolite provides stronger evidence of mast cell activation than histamine (multiple cellular sources) or tryptase (may reflect mast cell number rather than activation)
- MCAS diagnostic criterion: elevated PGD2 metabolite is one of the accepted mediator criteria for mast cell activation syndrome diagnosis in the proposed consensus frameworks. It identifies the prostaglandin-predominant MCAS subtype that tryptase and histamine testing may miss
- Catches prostaglandin-predominant activation: some MCAS patients present with PGD2-mediated symptoms (flushing, bronchoconstriction, hypotension) as the dominant manifestation rather than histamine-mediated symptoms. Their N-methylhistamine may be normal while PGD2 metabolite is elevated. Without PGD2 testing, these patients are missed
- Completes the mediator panel: the three-mediator approach (tryptase + histamine/NMH + PGD2 metabolite) casts the widest diagnostic net. Each marker captures a different mediator pathway, and patients may be positive on one, two, or all three depending on their individual mediator profile
- Treatment guidance: elevated PGD2 directs the use of COX inhibitors (aspirin, if tolerated) and leukotriene receptor antagonists (montelukast) as specific prostaglandin-pathway interventions, in addition to standard mast cell stabilizers
- Mastocytosis monitoring: in systemic mastocytosis, PGD2 metabolite tracks the prostaglandin component of disease burden and monitors response to cytoreductive therapy
3. Standard Lab Reference Range
| Collection Type | Reference | Notes |
|---|---|---|
| Spot urine (creatinine-corrected) | Laboratory-specific | Most convenient; corrected for dilution; adequate for screening |
| 24-hour urine | Laboratory-specific | More comprehensive; integrates full daily PGD2 production |
| Elevated | Above upper limit of normal | Confirms mast cell prostaglandin mediator excess; clinical correlation required |
4. Functional Medicine Interpretation
| Result | Interpretation | Clinical Action |
|---|---|---|
| Normal PGD2, normal tryptase, normal NMH | Mast cell activation unlikely by current mediator criteria | Consider alternative diagnoses; mast cell activation not excluded (mediator testing sensitivity is imperfect) |
| Elevated PGD2, normal tryptase, normal NMH | Prostaglandin-predominant mast cell activation confirmed | MCAS diagnosis supported; add aspirin (if tolerated) and montelukast to mast cell stabilization protocol |
| Elevated PGD2, elevated NMH, normal tryptase | Combined histamine and prostaglandin mast cell activation | Full MCAS protocol: H1/H2 blockade + mast cell stabilizer + COX inhibitor + leukotriene blockade |
| Elevated PGD2, elevated tryptase | Mast cell activation with elevated mast cell burden | Evaluate for systemic mastocytosis; hematology referral if tryptase above 20 ng/mL persistently |
The aspirin caution: aspirin and NSAIDs must be discontinued 48 to 72 hours before PGD2 metabolite collection because they inhibit COX, the enzyme required for PGD2 synthesis. Taking aspirin during the collection produces a false-negative result. Paradoxically, aspirin is also a treatment for PGD2-mediated symptoms once the diagnosis is confirmed. The key distinction: stop aspirin to diagnose, restart aspirin to treat. Acetaminophen does not significantly affect COX-mediated PGD2 production and is acceptable during the preparation period.
5. PGD2 Metabolite in the Complete Mast Cell Mediator Panel
| Marker | Mediator Pathway | Mast Cell Specificity |
|---|---|---|
| Urinary PGD2 Metabolite (this page) | Cyclooxygenase / prostaglandin pathway | Highest: almost exclusively mast cell |
| Urinary N-Methylhistamine | Histamine pathway | Moderate: mast cells + basophils + gut bacteria + gastric cells |
| Serum Tryptase (baseline) | Mast cell granule protease | High for mast cell number; moderate for activation (may be normal in MCAS) |
| Serum Tryptase (acute) | Mast cell degranulation event | High when acute rise above baseline (20% + 2 rule) is captured |
| Plasma Histamine | Immediate histamine release | Moderate; very short half-life limits clinical utility |
| Leukotriene E4 (urine) | Leukotriene pathway | Moderate: mast cells + eosinophils + basophils |
6. Symptoms Mediated by PGD2
DP1 and DP2 (CRTH2) Receptor Effects
- Flushing (PGD2-mediated vasodilation through DP1)
- Hypotension during mast cell activation episodes
- Nasal congestion (vascular engorgement)
- Bronchoconstriction and wheezing
- Airway inflammation and mucus hypersecretion
- Eosinophil recruitment to airways and tissues (via CRTH2/DP2)
- Th2 immune polarization (driving allergic-type inflammation)
Systemic PGD2 Effects
- Sleep induction and drowsiness (PGD2 is a physiological sleep promoter in the CNS)
- Niacin-type flushing reaction (PGD2 mediates the niacin flush)
- Abdominal cramping and GI dysmotility
- Bone pain (PGD2 in mastocytosis with marrow involvement)
- Headache (vasodilatory mechanism)
- Platelet aggregation inhibition (DP1-mediated)
- Hair loss (PGD2 implicated in androgenic alopecia through DP2 in hair follicles)
7. What Causes Elevated Urinary PGD2 Metabolite
- Mast cell activation syndrome (MCAS): inappropriate mast cell degranulation releases PGD2 through the COX pathway. Prostaglandin-predominant MCAS patients may have elevated PGD2 metabolite as their only abnormal mediator marker
- Systemic mastocytosis: the increased mast cell burden in mastocytosis produces constitutively elevated PGD2 alongside elevated tryptase and histamine
- Anaphylaxis: severe mast cell degranulation during anaphylaxis releases large quantities of PGD2. Urinary PGD2 metabolite collected within hours of anaphylaxis confirms the mast cell origin of the reaction
- Niacin (vitamin B3) ingestion: niacin induces the flushing response through PGD2 release from dermal Langerhans cells and mast cells. Niacin should be avoided during the collection period
- Aspirin-exacerbated respiratory disease (AERD): also known as Samter's triad (asthma + nasal polyps + aspirin sensitivity). PGD2 is overproduced in AERD through dysregulated arachidonic acid metabolism
- Allergic inflammation: mast cells activated through IgE-mediated allergic responses release PGD2 as part of the early-phase allergic reaction, though this is typically in the context of a known allergen exposure
8. How to Reduce PGD2-Mediated Mast Cell Symptoms
Prostaglandin Pathway Blockade
- Aspirin (81 to 325mg daily, if tolerated): inhibits COX and directly reduces PGD2 synthesis. The most targeted pharmaceutical intervention for PGD2-mediated symptoms. Caution: some MCAS patients are aspirin-sensitive; start with 81mg and observe for reactions
- Montelukast (10mg daily): leukotriene receptor antagonist that blocks CysLT1 receptor. Leukotrienes are co-released with PGD2 from mast cells. Particularly useful for bronchoconstriction, nasal congestion, and airway inflammation
- DP2 (CRTH2) receptor antagonists: emerging therapeutic class that blocks the PGD2-DP2 pathway responsible for eosinophil recruitment and Th2 polarization. Not yet widely available but actively studied in MCAS and eosinophilic conditions
Mast Cell Stabilization
- Quercetin (500mg twice daily): natural mast cell stabilizer that reduces degranulation and thereby reduces PGD2, histamine, and leukotriene release at the source. Acts upstream of all mediator pathways
- Cromolyn sodium: pharmaceutical mast cell stabilizer that prevents degranulation. Oral form (Gastrocrom) for GI symptoms; nebulized for respiratory symptoms
- Luteolin (100 to 200mg daily): flavonoid mast cell stabilizer often combined with quercetin for synergistic stabilization
- H1/H2 antihistamines: cetirizine 10mg twice daily (H1) + famotidine 20mg twice daily (H2) for concurrent histamine-mediated symptoms, which often coexist with PGD2 elevation
- Vitamin C (1000 to 2000mg daily): mast cell membrane stabilization and histamine degradation support
Root Cause and Trigger Reduction
- Trigger identification: common MCAS triggers that provoke PGD2 release include temperature changes, physical exertion, emotional stress, certain medications, fragrances, and food additives. Systematic trigger identification and avoidance reduces activation frequency
- Low-histamine diet: while primarily targeting histamine, the low-histamine diet reduces overall mast cell triggering load, which reduces PGD2 co-release
- Gut barrier restoration: intestinal permeability allows food-derived and microbial antigens to trigger mucosal mast cells. Gut restoration reduces the antigenic load driving mast cell activation
- Stress reduction: corticotropin-releasing hormone directly activates mast cells. Chronic stress perpetuates the mast cell activation cycle and PGD2 production
- Omega-3 fatty acids (2 to 3g EPA/DHA daily): compete with arachidonic acid as COX substrate, shifting prostaglandin production away from pro-inflammatory PGD2 toward less inflammatory prostaglandins
9. Related Lab Tests
Serum TryptaseMast Cell Number and Degranulation
→
hs-CRPSystemic Inflammation Context
→
CortisolStress Axis; CRH Activates Mast Cells
→
Vitamin DImmune Modulation; Mast Cell Regulation
→
ZincDAO Cofactor; Immune Support
→
FerritinElevated in Mastocytosis
→
10. When Testing Is Recommended
- Suspected MCAS with normal tryptase and normal N-methylhistamine: PGD2 metabolite catches prostaglandin-predominant activation that other markers miss
- Comprehensive mast cell mediator panel: alongside tryptase and urinary N-methylhistamine for maximum diagnostic sensitivity across all three mediator pathways
- Flushing-predominant presentations: PGD2 is a primary vasodilator in mast cell-mediated flushing, and PGD2 metabolite may be the only elevated marker in these patients
- Bronchoconstriction or respiratory symptoms with suspected mast cell origin
- Aspirin-exacerbated respiratory disease (AERD/Samter's triad) evaluation
- Post-anaphylaxis evaluation: confirms mast cell-specific prostaglandin release as a component of the anaphylactic reaction
- Monitoring treatment response to aspirin, montelukast, and mast cell stabilization in confirmed MCAS or mastocytosis
- Collection preparation: avoid aspirin, NSAIDs, and niacin for 48 to 72 hours before collection (discuss with physician). Acetaminophen is acceptable. Refrigerate sample during collection
11. Clinical Perspective
Clinical Perspective
PGD2 metabolite is the marker I order when tryptase and N-methylhistamine are both normal and I still believe the patient has mast cell disease. The three-mediator panel exists because mast cell activation is not a single-mediator phenomenon. Some patients release primarily histamine. Others release primarily prostaglandins. Some release primarily leukotrienes. If I only check tryptase and histamine, I miss the prostaglandin-predominant patients entirely. The patient who flushes intensely, drops blood pressure during episodes, and has bronchoconstriction but a normal tryptase and normal N-methylhistamine is the exact patient who needs the PGD2 metabolite checked. When it comes back elevated, the diagnosis becomes clear and the treatment becomes specific: aspirin (if tolerated), montelukast, and mast cell stabilization. The mediator panel is a net. Tryptase is one strand. Histamine is another. PGD2 is the third. You need all three strands to catch the fish.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
12. Frequently Asked Questions
What is urinary PGD2 metabolite?
The stable urinary metabolite of prostaglandin D2 (PGD2), measured as 11-beta-PGF2alpha or 2,3-dinor-11-beta-PGF2alpha. PGD2 is produced almost exclusively by mast cells through the COX pathway, making its metabolite the most mast cell-specific mediator marker available. Spot or 24-hour urine collection, refrigerated.
Why is PGD2 more specific to mast cells than histamine or tryptase?
Histamine comes from mast cells, basophils, gut bacteria, and gastric cells. Tryptase reflects mast cell number but may be normal in MCAS. PGD2 is produced almost exclusively by mast cells through hematopoietic PGD synthase (H-PGDS). Basophils produce minimal PGD2. Elevated PGD2 metabolite provides the strongest evidence that mast cells specifically are the activated cell type.
How is urinary PGD2 metabolite collected?
Spot urine (creatinine-corrected) or 24-hour urine collection, refrigerated. Avoid aspirin, NSAIDs, and niacin for 48 to 72 hours before collection (discuss with physician) because these inhibit COX and reduce PGD2 production, producing false-negative results. Acetaminophen is acceptable during the preparation period.
What does elevated PGD2 metabolite mean?
Confirms mast cell prostaglandin mediator excess. Supports MCAS diagnosis when combined with compatible symptoms. Identifies prostaglandin-predominant MCAS subtype missed by tryptase or histamine alone. Directs treatment toward COX inhibition (aspirin) and leukotriene blockade (montelukast) in addition to standard mast cell stabilization.
Can aspirin or NSAIDs affect PGD2 metabolite results?
Yes. Aspirin and NSAIDs inhibit COX, required for PGD2 synthesis, producing false-negative results. Discontinue 48 to 72 hours before collection if clinically safe. Paradoxically, aspirin is also a treatment for PGD2-mediated symptoms once diagnosed. Stop aspirin to diagnose; restart to treat. Acetaminophen does not significantly affect PGD2 production.
Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
PGD2 metabolite is the third strand in the mast cell mediator net. Without it, prostaglandin-predominant activation is invisible.
The complete mast cell mediator panel includes tryptase, N-methylhistamine, and PGD2 metabolite. Three mediator pathways, one comprehensive assessment. Schedule a consultation at The Lamkin Clinic.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Mast cell mediator testing requires proper collection technique, medication preparation, and clinical interpretation. Lab interpretation should always be performed by a qualified healthcare provider. Schedule a consultation to discuss your specific results with Brian Lamkin, DO.